MMP10 and lung cancer: A potential consequence of this limited molecular complementarity, in an in vivo setting characterized by multiple MMPs competing for a limited pool of TIMPs, may be an excess of residual active MMP-10, a situation that may contribute to pathogenesis in diseases such as lung cancer [16], [17], [18].